Visiongain Publishes Biochips Market Report 2020-2030

05 August 2020
Pharma

Visiongain has launched a new pharma report Biochips Market Report 2020-2030: Forecasts by Product Type (DNA Chip, Protein Chip, Enzyme Chip, Lab-on-a-Chip), Fabrication Techniques (Microarray, Microfluidics), Analysis Methods (Electrophoresis, Luminescence, Mass Spectrometry, Electrical Signals, Magnetism), Applications (Molecular Analysis, Diagnostics, Non-Biological Usage), End-use (Biotech & Pharma, Hospitals & Diagnostics Centers, Academic & Research Institutes, Others), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). PLUS Profiles of Leading Biochips Companies and COVID-19 Impact Analysis.

This report evaluates the biochips market for the period, 2020-2030. The global biochips market is estimated to be worth US$ xx million in 2020 and is projected to reach US$ xx million in 2030 while growing at a CAGR of xx% over the forecast period from 2020 to 2030.

As the field of nanofluidic matures, fundamental discoveries are being applied to lab-on-a-chip analyses. The unique behavior of matter at the nanoscale is adding new functionality to devices that integrate nanopores or nanochannels allowing for single-molecule interactions or single-molecule DNA-sequencing.

Nanoelectronics has already reached the level of maturity needed for such biochips. Nevertheless, challenges came up regarding the combination of sensors with microarrays that allow users to look at thousands of genes or proteins in parallel in a single experiment. Novel magnetic sensors are used in combination with these DNA microarrays to improve a single molecule investigation of DNA and DNA/protein interactions.

“Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis. Biochip technology is regarded as a key technology, ensuring the cost efficiency required. The technology is also gaining increasing significance as a 'diagnostic of the future'."
Industry Analyst, Visiongain 2020

Today’s methods for disease/cancer diagnostics require taking invasive samples to be sent to a clinical laboratory with specialized and expensive biotechnology equipment that runs time-consuming tests to get a report on the analysis of that sample. Accurate analysis requires a certain amount of time and sample and therefore, far away from today’s requirements for rapid diagnostics and treatment. Doctors and patients are expecting Point-of-Care multiple tests at the same time with increased efficiency and speed. This would allow doctors to decide quickly and in the early stages of disease for its treatment. In areas like cardiovascular diseases, cancer, and chronic illnesses, this would be a paramount tool increasing the success rate of both doctors and patients in treating a medical condition. On the other side, some biotechnology areas recognize the early stage of biochip developments and therefore, expect advances of areas like micro/nanofluidic, nanoelectronics, and biotech to influence biochips development that together with a processing unit provides accurate, local, fast and cheap analysis or diagnosis. Those specialized biotech areas include DNA applications (gene expression, SNP genotyping, agricultural and zoological biotechnology) and Protein microarray applications (expression profiling, proteomics, high throughput screening, and drug discovery).

Some of the major companies operating in the global biochips market are Illumina, Inc., Agilent Technologies, Danaher Corporation, Fluidigm Corporation, Perkin Elmer, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Merck KgaA, and Cellix, Ltd. among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever